101
|
Miska J, Rashidi A, Chang AL, Muroski ME, Han Y, Zhang L, Lesniak MS. Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol Immunother 2016; 65:1555-1567. [PMID: 27734112 DOI: 10.1007/s00262-016-1912-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Accepted: 09/30/2016] [Indexed: 01/06/2023]
Abstract
Regulatory T cells (Tregs) are potently immunosuppressive cells that accumulate within the glioma microenvironment. The reduction in their function and/or trafficking has been previously shown to enhance survival in preclinical models of glioma. Glucocorticoid-induced TNFR-related protein (GITR) is a tumor necrosis factor superfamily receptor enriched on Tregs that has shown promise as a target for immunotherapy. An agonistic antibody against GITR has been demonstrated to inhibit Tregs in a number of models and has only been recently addressed in glioma. In this study, we examined the modality of the antibody function at the tumor site as opposed to the periphery as the blood-brain barrier prevents efficient antibody delivery to brain tumors. Mice harboring established GL261 tumors were treated with anti-GITR monotherapy and were shown to have a significant increase in overall survival (p < 0.01) when antibodies were injected directly into the glioma core, whereas peripheral antibody treatment only had a modest effect. Peripheral treatment resulted in a significant decrease in granzyme B (GrB) expression by Tregs, whereas intratumoral treatment resulted in both a decrease in GrB expression by Tregs and their selective depletion, which was largely mediated by FcγR-mediated destruction. We also discovered that anti-GITR treatment results in the enhanced survival and functionality of dendritic cells (DCs)-a previously unreported effect of this immunotherapy. In effect, this study demonstrates that the targeting of GITR is a feasible and noteworthy treatment option for glioma, but is largely dependent on the anatomical location in which the antibodies are delivered.
Collapse
Affiliation(s)
- Jason Miska
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, 676 N St. Clair, Suite 2210, Chicago, IL 60611, USA
| | - Aida Rashidi
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, 676 N St. Clair, Suite 2210, Chicago, IL 60611, USA
| | - Alan L Chang
- Committee on Cancer Biology, The University of Chicago, Chicago, IL, USA
| | - Megan E Muroski
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, 676 N St. Clair, Suite 2210, Chicago, IL 60611, USA
| | - Yu Han
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, 676 N St. Clair, Suite 2210, Chicago, IL 60611, USA
| | - Lingjiao Zhang
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, 676 N St. Clair, Suite 2210, Chicago, IL 60611, USA
| | - Maciej S Lesniak
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, 676 N St. Clair, Suite 2210, Chicago, IL 60611, USA
| |
Collapse
|
102
|
Lee G, Auffinger B, Guo D, Hasan T, Deheeger M, Tobias AL, Kim JY, Atashi F, Zhang L, Lesniak MS, James CD, Ahmed AU. Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model. Mol Cancer Ther 2016; 15:3064-3076. [PMID: 27765847 DOI: 10.1158/1535-7163.mct-15-0675] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Revised: 09/23/2016] [Accepted: 09/25/2016] [Indexed: 12/12/2022]
Abstract
Increasing evidence exposes a subpopulation of cancer cells, known as cancer stem cells (CSCs), to be critical for the progression of several human malignancies, including glioblastoma multiforme. CSCs are highly tumorigenic, capable of self-renewal, and resistant to conventional therapies, and thus considered to be one of the key contributors to disease recurrence. To elucidate the poorly understood evolutionary path of tumor recurrence and the role of CSCs in this process, we developed patient-derived xenograft glioblastoma recurrent models induced by anti-glioma chemotherapy, temozolomide. In this model, we observed a significant phenotypic shift towards an undifferentiated population. We confirmed these findings in vitro as sorted CD133-negative populations cultured in differentiation-forcing media were found to acquire CD133 expression following chemotherapy treatment. To investigate this phenotypic switch at the single-cell level, glioma stem cell (GSC)-specific promoter-based reporter systems were engineered to track changes in the GSC population in real time. We observed the active phenotypic and functional switch of single non-stem glioma cells to a stem-like state and that temozolomide therapy significantly increased the rate of single-cell conversions. Importantly, we showed the therapy-induced hypoxia-inducible factors (HIF) 1α and HIF2α play key roles in allowing non-stem glioma cells to acquire stem-like traits, as the expression of both HIFs increase upon temozolomide therapy and knockdown of HIFs expression inhibits the interconversion between non-stem glioma cells and GSCs post-therapy. On the basis of our results, we propose that anti-glioma chemotherapy promotes the accumulation of HIFs in the glioblastoma multiforme cells that induces the formation of therapy-resistant GSCs responsible for recurrence. Mol Cancer Ther; 15(12); 3064-76. ©2016 AACR.
Collapse
Affiliation(s)
- Gina Lee
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Brenda Auffinger
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Donna Guo
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Tanwir Hasan
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Marc Deheeger
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Alex L Tobias
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Jeong Yeon Kim
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Fatemeh Atashi
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Lingjiao Zhang
- Department of Surgery, University of Chicago, Chicago, Illinois
| | - Maciej S Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - C David James
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Atique U Ahmed
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
| |
Collapse
|
103
|
Abstract
Adenoviral vectors have proven to be valuable resources in the development of novel therapies aimed at targeting pathological conditions of the central nervous system, including Alzheimer's disease and neoplastic brain lesions. Not only can some genetically engineered adenoviral vectors achieve remarkably efficient and specific gene delivery to target cells, but they also may act as anticancer agents by selectively replicating within cancer cells.Due to the great interest in using adenoviral vectors for various purposes, the need for a comprehensive protocol for viral vector production is especially apparent. Here, we describe the process of generating an adenoviral vector in its entirety, including the more complex process of adenoviral fiber modification to restrict viral tropism in order to achieve more efficient and specific gene delivery.
Collapse
Affiliation(s)
- Julius W Kim
- The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 3026, Chicago, IL, USA
| | - Ramin A Morshed
- The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 3026, Chicago, IL, USA
| | - J Robert Kane
- The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 3026, Chicago, IL, USA
| | - Brenda Auffinger
- The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 3026, Chicago, IL, USA
| | - Jian Qiao
- The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 3026, Chicago, IL, USA
| | - Maciej S Lesniak
- The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 3026, Chicago, IL, USA.
| |
Collapse
|
104
|
Dey M, Yu D, Kanojia D, Li G, Sukhanova M, Spencer DA, Pituch KC, Zhang L, Han Y, Ahmed AU, Aboody KS, Lesniak MS, Balyasnikova IV. Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma. Stem Cell Reports 2016; 7:471-482. [PMID: 27594591 PMCID: PMC5032402 DOI: 10.1016/j.stemcr.2016.07.024] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 07/28/2016] [Accepted: 07/29/2016] [Indexed: 02/06/2023] Open
Abstract
The challenges to effective drug delivery to brain tumors are twofold: (1) there is a lack of non-invasive methods of local delivery and (2) the blood-brain barrier limits systemic delivery. Intranasal delivery of therapeutics to the brain overcomes both challenges. In mouse model of malignant glioma, we observed that a small fraction of intranasally delivered neural stem cells (NSCs) can migrate to the brain tumor site. Here, we demonstrate that hypoxic preconditioning or overexpression of CXCR4 significantly enhances the tumor-targeting ability of NSCs, but without altering their phenotype only in genetically modified NSCs. Modified NSCs deliver oncolytic virus to glioma more efficiently and extend survival of experimental animals in the context of radiotherapy. Our findings indicate that intranasal delivery of stem cell-based therapeutics could be optimized for future clinical applications, and allow for safe and repeated administration of biological therapies to brain tumors and other CNS disorders. Intranasal delivery of NSCs is a promising platform for glioma therapy Hypoxia or CXCR4 overexpression enhances NSC migration to glioma Oncolytic viruses loaded in CXCR4-enhanced NSCs improve animal survival Non-invasive intranasal NSC-based therapies warrant clinical translation
Collapse
Affiliation(s)
- Mahua Dey
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA
| | - Dou Yu
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Deepak Kanojia
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Gina Li
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA
| | - Madina Sukhanova
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
| | - Drew A Spencer
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Katatzyna C Pituch
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Lingjiao Zhang
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA
| | - Yu Han
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Atique U Ahmed
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Karen S Aboody
- Division of Neurosurgery, Department of Neurosciences, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
| | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - Irina V Balyasnikova
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA; Department of Neurological Surgery, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| |
Collapse
|
105
|
Abstract
Von Hippel-Lindau disease is a genetic condition due to mutation of the Von Hippel-Lindau gene, which leads to an increased risk in the development of hemangioblastomas of the brain and spinal cord. The pathophysiology of disease and its clinical manifestations, as they pertain to the general neurologist, are discussed. Therapeutic management of central nervous system hemangioblastomas ranging from neurosurgical resection, radiation therapy, and systemic therapies is reviewed.
Collapse
Affiliation(s)
- Trent S Hodgson
- *Department of Neurology, Cornell University, New York, NY †Department of Medicine-Section of Hematology & Oncology, University of Chicago ‡Department of Neurosurgery §Department of Neurology, University of Chicago, Chicago
| | | | | | | |
Collapse
|
106
|
Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, Han Y, Wu M, Zhang L, Horbinski CM, Ahmed AU, Lesniak MS. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer Res 2016; 76:5671-5682. [PMID: 27530322 DOI: 10.1158/0008-5472.can-16-0144] [Citation(s) in RCA: 402] [Impact Index Per Article: 50.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Accepted: 07/07/2016] [Indexed: 12/15/2022]
Abstract
In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). However, the mechanistic details of how Tregs and MDSCs are recruited in various tumors are not yet well understood. Here we report that macrophages and microglia within the glioma microenvironment produce CCL2, a chemokine that is critical for recruiting both CCR4+ Treg and CCR2+Ly-6C+ monocytic MDSCs in this disease setting. In murine gliomas, we established novel roles for tumor-derived CCL20 and osteoprotegerin in inducing CCL2 production from macrophages and microglia. Tumors grown in CCL2-deficient mice failed to maximally accrue Tregs and monocytic MDSCs. In mixed-bone marrow chimera assays, we found that CCR4-deficient Treg and CCR2-deficient monocytic MDSCs were defective in glioma accumulation. Furthermore, administration of a small-molecule antagonist of CCR4 improved median survival in the model. In clinical specimens of glioblastoma multiforme, elevated levels of CCL2 expression correlated with reduced overall survival of patients. Finally, we found that CD163-positive infiltrating macrophages were a major source of CCL2 in glioblastoma multiforme patients. Collectively, our findings show how glioma cells influence the tumor microenvironment to recruit potent effectors of immunosuppression that drive progression. Cancer Res; 76(19); 5671-82. ©2016 AACR.
Collapse
Affiliation(s)
- Alan L Chang
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Committee on Cancer Biology, The University of Chicago, Chicago, Illinois
| | - Jason Miska
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Derek A Wainwright
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Mahua Dey
- Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana. Section of Neurosurgery, Department of Surgery, The University of Chicago Hospitals, Chicago, Illinois
| | - Claudia V Rivetta
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Dou Yu
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Deepak Kanojia
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Katarzyna C Pituch
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Jian Qiao
- Section of Neurosurgery, Department of Surgery, The University of Chicago Hospitals, Chicago, Illinois. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Peter Pytel
- Department of Pathology, The University of Chicago, Chicago, Illinois
| | - Yu Han
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Meijing Wu
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Lingjiao Zhang
- Section of Neurosurgery, Department of Surgery, The University of Chicago Hospitals, Chicago, Illinois
| | - Craig M Horbinski
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Atique U Ahmed
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Maciej S Lesniak
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
| |
Collapse
|
107
|
Roth S, Dreixler JC, Mathew B, Balyasnikova I, Mann JR, Boddapati V, Xue L, Lesniak MS. Hypoxic-Preconditioned Bone Marrow Stem Cell Medium Significantly Improves Outcome After Retinal Ischemia in Rats. Invest Ophthalmol Vis Sci 2016; 57:3522-32. [PMID: 27367588 PMCID: PMC4961056 DOI: 10.1167/iovs.15-17381] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Accepted: 04/28/2016] [Indexed: 12/20/2022] Open
Abstract
PURPOSE We have previously demonstrated the protective effect of bone marrow stem cell (BMSC)-conditioned medium in retinal ischemic injury. We hypothesized here that hypoxic preconditioning of stem cells significantly enhances the neuroprotective effect of the conditioned medium and thereby augments the protective effect in ischemic retina. METHODS Rats were subjected to retinal ischemia by increasing intraocular pressure to 130 to 135 mm Hg for 55 minutes. Hypoxic-preconditioned, hypoxic unconditioned, or normoxic medium was injected into the vitreous 24 hours after ischemia ended. Recovery was assessed 7 days after injections by comparing electroretinography measurements, histologic examination, and apoptosis (TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay). To compare proteins secreted into the medium in the groups and the effect of hypoxic exposure, we used rat cytokine arrays. RESULTS Eyes injected with hypoxic BMSC-conditioned medium 24 hours after ischemia demonstrated significantly enhanced return of retinal function, decreased retinal ganglion cell layer loss, and attenuated apoptosis compared to those administered normoxic or hypoxic unconditioned medium. Hypoxic-preconditioned medium had 21 significantly increased protein levels compared to normoxic medium. CONCLUSIONS The medium from hypoxic-preconditioned BMSCs robustly restored retinal function and prevented cell loss after ischemia when injected 24 hours after ischemia. The protective effect was even more pronounced than in our previous studies of normoxic conditioned medium. Prosurvival signals triggered by the secretome may play a role in this neuroprotective effect.
Collapse
Affiliation(s)
- Steven Roth
- Department of Anesthesiology, University of Illinois, Illinois, United States
- Department of Anesthesia and Critical Care, University of Chicago, Illinois, United States
| | - John C. Dreixler
- Department of Anesthesia and Critical Care, University of Chicago, Illinois, United States
| | - Biji Mathew
- Department of Anesthesiology, University of Illinois, Illinois, United States
| | - Irina Balyasnikova
- Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Surgery, University of Chicago Medicine, University of Chicago, Illinois, United States
| | - Jacob R. Mann
- Department of Anesthesia and Critical Care, University of Chicago, Illinois, United States
| | - Venkat Boddapati
- Department of Anesthesia and Critical Care, University of Chicago, Illinois, United States
| | - Lai Xue
- Surgery, University of Chicago Medicine, University of Chicago, Illinois, United States
| | - Maciej S. Lesniak
- Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Surgery, University of Chicago Medicine, University of Chicago, Illinois, United States
| |
Collapse
|
108
|
Morshed RA, Muroski ME, Dai Q, Wegscheid ML, Auffinger B, Yu D, Han Y, Zhang L, Wu M, Cheng Y, Lesniak MS. Cell-Penetrating Peptide-Modified Gold Nanoparticles for the Delivery of Doxorubicin to Brain Metastatic Breast Cancer. Mol Pharm 2016; 13:1843-54. [PMID: 27169484 DOI: 10.1021/acs.molpharmaceut.6b00004] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
As therapies continue to increase the lifespan of patients with breast cancer, the incidence of brain metastases has steadily increased, affecting a significant number of patients with metastatic disease. However, a major barrier toward treating these lesions is the inability of therapeutics to penetrate into the central nervous system and accumulate within intracranial tumor sites. In this study, we designed a cell-penetrating gold nanoparticle platform to increase drug delivery to brain metastatic breast cancer cells. TAT peptide-modified gold nanoparticles carrying doxorubicin led to improved cytotoxicity toward two brain metastatic breast cancer cell lines with a decrease in the IC50 of at least 80% compared to free drug. Intravenous administration of these particles led to extensive accumulation of particles throughout diffuse intracranial metastatic microsatellites with cleaved caspase-3 activity corresponding to tumor foci. Furthermore, intratumoral administration of these particles improved survival in an intracranial MDA-MB-231-Br xenograft mouse model. Our results demonstrate the promising application of gold nanoparticles for improving drug delivery in the context of brain metastatic breast cancer.
Collapse
Affiliation(s)
- Ramin A Morshed
- The Brain Tumor Center, The University of Chicago , Chicago, Illinois United States
| | - Megan E Muroski
- Northwestern University Feinberg School of Medicine , 676 North Saint Clair Street, Suite 2210, Chicago, Illinois 60611, United States
| | - Qing Dai
- Department of Chemistry, Institute of Biophysics Dynamics and Howard Hughes Medical Institute, The University of Chicago , Chicago, Illinois United States
| | - Michelle L Wegscheid
- The Brain Tumor Center, The University of Chicago , Chicago, Illinois United States
| | - Brenda Auffinger
- The Brain Tumor Center, The University of Chicago , Chicago, Illinois United States
| | - Dou Yu
- Northwestern University Feinberg School of Medicine , 676 North Saint Clair Street, Suite 2210, Chicago, Illinois 60611, United States
| | - Yu Han
- Northwestern University Feinberg School of Medicine , 676 North Saint Clair Street, Suite 2210, Chicago, Illinois 60611, United States
| | - Lingjiao Zhang
- The Brain Tumor Center, The University of Chicago , Chicago, Illinois United States
| | - Meijing Wu
- Northwestern University Feinberg School of Medicine , 676 North Saint Clair Street, Suite 2210, Chicago, Illinois 60611, United States
| | - Yu Cheng
- Shanghai East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine , Shanghai, China
| | - Maciej S Lesniak
- Northwestern University Feinberg School of Medicine , 676 North Saint Clair Street, Suite 2210, Chicago, Illinois 60611, United States
| |
Collapse
|
109
|
Kim JW, Auffinger B, Spencer DA, Miska J, Chang AL, Kane JR, Young JS, Kanojia D, Qiao J, Mann JF, Zhang L, Wu M, Ahmed AU, Aboody KS, Strong TV, Hébert CD, Lesniak MS. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. J Transl Med 2016; 14:134. [PMID: 27184224 PMCID: PMC4868110 DOI: 10.1186/s12967-016-0895-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Accepted: 05/05/2016] [Indexed: 11/11/2022] Open
Abstract
Background CRAd-S-pk7 is a conditionally replicative oncolytic adenoviral vector that contains a survivin promoter and a pk7 fiber modification that confer tumor-specific transcriptional targeting and preferential replication in glioma while sparing the surrounding normal brain parenchyma. Methods This IND-enabling study performed under GLP conditions evaluated the toxicity and biodistribution of CRAd-S-pk7 administered as a single intracerebral dose to Syrian hamsters, a permissive model of adenoviral replication. Two hundred and forty animals were stereotactically administered either vehicle (n = 60) or CRAd-S-pk7 at 2.5 × 107, 2.5 × 108, or 2.5 × 109 viral particles (vp)/animal (each n = 60) on day 1. The animals were closely monitored for toxicology evaluation, assessment of viral distribution, and immunogenicity of CRAd-S-pk7. Results Changes in hematology, clinical chemistry, and coagulation parameters were minor and transient, and consistent with the inflammatory changes observed microscopically. These changes were considered to be of little toxicological significance. The vector remained localized primarily in the brain and to some degree in the tissues at the incision site. Low levels of vector DNA were detected in other tissues in a few animals suggesting systemic circulation of the virus. Viral DNA was detected in brains of hamsters for up to 62 days. However, microscopic changes and virus-related toxicity to the central nervous system were considered minor and decreased in incidence and severity over time. Such changes are not uncommon in studies using adenoviral vectors. Conclusion This study provides safety and toxicology data justifying a clinical trial of CRAd-S-pk7 loaded in FDA-approved HB1.F3.CD neural stem cell carriers administered at the tumor resection bed in humans with recurrent malignant glioma. Electronic supplementary material The online version of this article (doi:10.1186/s12967-016-0895-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Julius Woongki Kim
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Brenda Auffinger
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Drew A Spencer
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Jason Miska
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Alan L Chang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Joshua Robert Kane
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Jacob S Young
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Deepak Kanojia
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Jian Qiao
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Jill F Mann
- Southern Research Institute, Birmingham, AL, USA
| | - Lingjiao Zhang
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Meijing Wu
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | - Atique U Ahmed
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA
| | | | | | | | - Maciej S Lesniak
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St Clair St, Suite 2210, Chicago, IL, 60611, USA.
| |
Collapse
|
110
|
Cheng Y, Muroski ME, Petit DCMC, Mansell R, Vemulkar T, Morshed RA, Han Y, Balyasnikova IV, Horbinski CM, Huang X, Zhang L, Cowburn RP, Lesniak MS. Rotating magnetic field induced oscillation of magnetic particles for in vivo mechanical destruction of malignant glioma. J Control Release 2016; 223:75-84. [PMID: 26708022 PMCID: PMC4724455 DOI: 10.1016/j.jconrel.2015.12.028] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Revised: 11/27/2015] [Accepted: 12/16/2015] [Indexed: 01/05/2023]
Abstract
Magnetic particles that can be precisely controlled under a magnetic field and transduce energy from the applied field open the way for innovative cancer treatment. Although these particles represent an area of active development for drug delivery and magnetic hyperthermia, the in vivo anti-tumor effect under a low-frequency magnetic field using magnetic particles has not yet been demonstrated. To-date, induced cancer cell death via the oscillation of nanoparticles under a low-frequency magnetic field has only been observed in vitro. In this report, we demonstrate the successful use of spin-vortex, disk-shaped permalloy magnetic particles in a low-frequency, rotating magnetic field for the in vitro and in vivo destruction of glioma cells. The internalized nanomagnets align themselves to the plane of the rotating magnetic field, creating a strong mechanical force which damages the cancer cell structure inducing programmed cell death. In vivo, the magnetic field treatment successfully reduces brain tumor size and increases the survival rate of mice bearing intracranial glioma xenografts, without adverse side effects. This study demonstrates a novel approach of controlling magnetic particles for treating malignant glioma that should be applicable to treat a wide range of cancers.
Collapse
Affiliation(s)
- Yu Cheng
- Shanghai East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji University School of Medicine, Shanghai, China; The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, United States
| | - Megan E Muroski
- Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States
| | - Dorothée C M C Petit
- Thin Film Magnetism Group, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - Rhodri Mansell
- Thin Film Magnetism Group, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - Tarun Vemulkar
- Thin Film Magnetism Group, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - Ramin A Morshed
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, United States
| | - Yu Han
- Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States
| | - Irina V Balyasnikova
- Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States
| | - Craig M Horbinski
- Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States
| | - Xinlei Huang
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, United States
| | - Lingjiao Zhang
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, United States
| | - Russell P Cowburn
- Thin Film Magnetism Group, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - Maciej S Lesniak
- Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United States.
| |
Collapse
|
111
|
Kim JW, Young JS, Solomaha E, Kanojia D, Lesniak MS, Balyasnikova IV. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors. Sci Rep 2015; 5:18133. [PMID: 26656559 PMCID: PMC4677343 DOI: 10.1038/srep18133] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Accepted: 11/13/2015] [Indexed: 11/10/2022] Open
Abstract
The generation of a targeting agent that strictly binds to IL13Rα2 will significantly expand the therapeutic potential for the treatment of IL13Rα2-expressing cancers. In order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13Rα2 monoclonal antibody and tested its binding properties. Furthermore, to demonstrate the potential therapeutic applicability of scFv47, we engineered an adenovirus by incorporating scFv47 as the targeting moiety in the viral fiber and characterized its properties in vitro and in vivo. The scFv47 binds to human recombinant IL13Rα2, but not to IL13Rα1 with a high affinity of 0.9 · 10−9 M, similar to that of the parental antibody. Moreover, the scFv47 successfully redirects adenovirus to IL13Rα2 expressing glioma cells both in vitro and in vivo. Our data validate scFv47 as a highly selective IL13Rα2 targeting agent and justify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the treatment of IL13Rα2-expressing glioma and other malignancies.
Collapse
Affiliation(s)
- Julius W Kim
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA
| | - Jacob S Young
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA
| | - Elena Solomaha
- Biophysics Core Facility, The University of Chicago, Chicago, IL 60637, USA
| | - Deepak Kanojia
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA
| | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA
| | | |
Collapse
|
112
|
Miska J, Chang AL, Rashidi A, Dey M, Han Y, Zhang L, Balyasnikova IV, Ahmed AU, Lesniak MS. The use of anti-GITR antibody treatment in a murine model of glioblastoma multiforme. J Immunother Cancer 2015. [PMCID: PMC4649309 DOI: 10.1186/2051-1426-3-s2-p236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
113
|
Krenciute G, Krebs S, Torres D, Dotti G, Lesniak MS, Balyasnikova IV, Gottschalk S. Charachterization and functional analysis of scFv-based CARs to redirect T cells to IL13Rα2-positive glioma. J Immunother Cancer 2015. [PMCID: PMC4645137 DOI: 10.1186/2051-1426-3-s2-p116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
114
|
Chang AL, Miska J, Wainwright DA, Dey M, Qiao J, Pytel P, Han Y, Zhang L, Balyasnikova IV, Ahmed AU, Lesniak MS. Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells. J Immunother Cancer 2015. [PMCID: PMC4645485 DOI: 10.1186/2051-1426-3-s2-p72] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
115
|
Kim J, Hall RR, Lesniak MS, Ahmed AU. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions. Viruses 2015; 7:6200-17. [PMID: 26633462 PMCID: PMC4690850 DOI: 10.3390/v7122921] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Revised: 10/28/2015] [Accepted: 11/03/2015] [Indexed: 12/22/2022] Open
Abstract
Oncolytic virotherapy for cancer is an innovative therapeutic option where the ability of a virus to promote cell lysis is harnessed and reprogrammed to selectively destroy cancer cells. Such treatment modalities exhibited antitumor activity in preclinical and clinical settings and appear to be well tolerated when tested in clinical trials. However, the clinical success of oncolytic virotherapy has been significantly hampered due to the inability to target systematic metastasis. This is partly due to the inability of the therapeutic virus to survive in the patient circulation, in order to target tumors at distant sites. An early study from various laboratories demonstrated that cells infected with oncolytic virus can protect the therapeutic payload form the host immune system as well as function as factories for virus production and enhance the therapeutic efficacy of oncolytic virus. While a variety of cell lineages possessed potential as cell carriers, copious investigation has established stem cells as a very attractive cell carrier system in oncolytic virotherapy. The ideal cell carrier desire to be susceptible to viral infection as well as support viral infection, maintain immunosuppressive properties to shield the loaded viruses from the host immune system, and most importantly possess an intrinsic tumor homing ability to deliver loaded viruses directly to the site of the metastasis—all qualities stem cells exhibit. In this review, we summarize the recent work in the development of stem cell-based carrier for oncolytic virotherapy, discuss the advantages and disadvantages of a variety of cell carriers, especially focusing on why stem cells have emerged as the leading candidate, and finally propose a future direction for stem cell-based targeted oncolytic virotherapy that involves its establishment as a viable treatment option for cancer patients in the clinical setting.
Collapse
Affiliation(s)
- Janice Kim
- The Department of Surgery and the Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA.
| | - Robert R Hall
- The Department of Surgery and the Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA.
| | - Maciej S Lesniak
- The Department of Surgery and the Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA.
| | - Atique U Ahmed
- The Department of Surgery and the Brain Tumor Center, The University of Chicago, Chicago, IL 60637, USA.
| |
Collapse
|
116
|
Kane JR, Miska J, Young JS, Kanojia D, Kim JW, Lesniak MS. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol 2015; 17 Suppl 2:ii24-ii36. [PMID: 25746089 DOI: 10.1093/neuonc/nou355] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Gene therapy offers a multidimensional set of approaches intended to treat and cure glioblastoma (GBM), in combination with the existing standard-of-care treatment (surgery and chemoradiotherapy), by capitalizing on the ability to deliver genes directly to the site of neoplasia to yield antitumoral effects. Four types of gene therapy are currently being investigated for their potential use in treating GBM: (i) suicide gene therapy, which induces the localized generation of cytotoxic compounds; (ii) immunomodulatory gene therapy, which induces or augments an enhanced antitumoral immune response; (iii) tumor-suppressor gene therapy, which induces apoptosis in cancer cells; and (iv) oncolytic virotherapy, which causes the lysis of tumor cells. The delivery of genes to the tumor site is made possible by means of viral and nonviral vectors for direct delivery of therapeutic gene(s), tumor-tropic cell carriers expressing therapeutic gene(s), and "intelligent" carriers designed to increase delivery, specificity, and tumoral toxicity against GBM. These vehicles are used to carry genetic material to the site of pathology, with the expectation that they can provide specific tropism to the desired site while limiting interaction with noncancerous tissue. Encouraging preclinical results using gene therapies for GBM have led to a series of human clinical trials. Although there is limited evidence of a therapeutic benefit to date, a number of clinical trials have convincingly established that different types of gene therapies delivered by various methods appear to be safe. Due to the flexibility of specialized carriers and genetic material, the technology for generating new and more effective therapies already exists.
Collapse
Affiliation(s)
- J Robert Kane
- Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Jason Miska
- Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Jacob S Young
- Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Deepak Kanojia
- Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Julius W Kim
- Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Maciej S Lesniak
- Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| |
Collapse
|
117
|
Cheng SH, Yu D, Tsai HM, Morshed RA, Kanojia D, Lo LW, Leoni L, Govind Y, Zhang L, Aboody KS, Lesniak MS, Chen CT, Balyasnikova IV. Dynamic In Vivo SPECT Imaging of Neural Stem Cells Functionalized with Radiolabeled Nanoparticles for Tracking of Glioblastoma. J Nucl Med 2015; 57:279-84. [PMID: 26564318 DOI: 10.2967/jnumed.115.163006] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 11/09/2015] [Indexed: 12/26/2022] Open
Abstract
UNLABELLED There is strong clinical interest in using neural stem cells (NSCs) as carriers for targeted delivery of therapeutics to glioblastoma. Multimodal dynamic in vivo imaging of NSC behaviors in the brain is necessary for developing such tailored therapies; however, such technology is lacking. Here we report a novel strategy for mesoporous silica nanoparticle (MSN)-facilitated NSC tracking in the brain via SPECT. METHODS (111)In was conjugated to MSNs, taking advantage of the large surface area of their unique porous feature. A series of nanomaterial characterization assays was performed to assess the modified MSN. Loading efficiency and viability of NSCs with (111)In-MSN complex were optimized. Radiolabeled NSCs were administered to glioma-bearing mice via either intracranial or systemic injection. SPECT imaging and bioluminescence imaging were performed daily up to 48 h after NSC injection. Histology and immunocytochemistry were used to confirm the findings. RESULTS (111)In-MSN complexes show minimal toxicity to NSCs and robust in vitro and in vivo stability. Phantom studies demonstrate feasibility of this platform for NSC imaging. Of significance, we discovered that decayed (111)In-MSN complexes exhibit strong fluorescent profiles in preloaded NSCs, allowing for ex vivo validation of the in vivo data. In vivo, SPECT visualizes actively migrating NSCs toward glioma xenografts in real time after both intracranial and systemic administrations. This is in agreement with bioluminescence live imaging, confocal microscopy, and histology. CONCLUSION These advancements warrant further development and integration of this technology with MRI for multimodal noninvasive tracking of therapeutic NSCs toward various brain malignancies.
Collapse
Affiliation(s)
- Shih-Hsun Cheng
- Department of Radiology, The University of Chicago, Chicago, Illinois
| | - Dou Yu
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Hsiu-Ming Tsai
- Department of Radiology, The University of Chicago, Chicago, Illinois
| | - Ramin A Morshed
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Deepak Kanojia
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Leu-Wei Lo
- Department of Radiology, The University of Chicago, Chicago, Illinois Institute of Biomedical Engineering and Nanomedicine, National Health Research Institute(s), Taiwan; and
| | - Lara Leoni
- Department of Radiology, The University of Chicago, Chicago, Illinois
| | - Yureve Govind
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Lingjiao Zhang
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Karen S Aboody
- Department of Neuroscience, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
| | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Chin-Tu Chen
- Department of Radiology, The University of Chicago, Chicago, Illinois
| | | |
Collapse
|
118
|
Kim JW, Kane JR, Young JS, Yu D, Miska J, Chang AL, Rashidi A, Ahmed A, Balyasnikova I, Lesniak MS. ATPS-41DENDRITIC CELL BASED IMMUNOTHERAPY OF MALIGNANT GLIOMA VIA A NOVEL CD8α+ DC TARGETED ADENOVIRAL VECTOR. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov204.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
119
|
Kim JW, Kane JR, Young JS, Chang AL, Kanojia D, Morshed RA, Miska J, Ahmed AU, Balyasnikova IV, Han Y, Zhang L, Curiel DT, Lesniak MS. A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma. Hum Gene Ther 2015; 26:635-46. [PMID: 26058317 DOI: 10.1089/hum.2015.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The dismal clinical context of advanced-grade glioma demands the development of novel therapeutic strategies with direct patient impact. Adenovirus-mediated virotherapy represents a potentially effective approach for glioma therapy. In this research, we generated a novel glioma-specific adenovirus by instituting more advanced genetic modifications that can maximize the efficiency and safety of therapeutic adenoviral vectors. In this regard, a glioma-specific targeted fiber was developed through the incorporation of previously published glioma-specific, phage-panned peptide (VWT peptide) on a fiber fibritin-based chimeric fiber, designated as "GliomaFF." We showed that the entry of this virus was highly restricted to glioma cells, supporting the specificity imparted by the phage-panned peptide. In addition, the stability of the targeting moiety presented by fiber fibritin structure permitted greatly enhanced infectivity. Furthermore, the replication of this virus was restricted in glioma cells by controlling expression of the E1 gene under the activity of the tumor-specific survivin promoter. Using this approach, we were able to explore the combinatorial efficacy of various adenoviral modifications that could amplify the specificity, infectivity, and exclusive replication of this therapeutic adenovirus in glioma. Finally, virotherapy with this modified virus resulted in up to 70% extended survival in an in vivo murine glioma model. These data demonstrate that this novel adenoviral vector is a safe and efficient treatment for this difficult malignancy.
Collapse
Affiliation(s)
- Julius W Kim
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - J Robert Kane
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Jacob S Young
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Alan L Chang
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Deepak Kanojia
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Ramin A Morshed
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Jason Miska
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Atique U Ahmed
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Irina V Balyasnikova
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Yu Han
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - Lingjiao Zhang
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| | - David T Curiel
- 2 Cancer Biology Division, Biologic Therapeutics Center, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis , St. Louis, Missouri
| | - Maciej S Lesniak
- 1 Brain Tumor Center, University of Chicago Pritzker School of Medicine , Chicago, Illinois
| |
Collapse
|
120
|
Kanojia D, Balyasnikova IV, Morshed RA, Frank RT, Yu D, Zhang L, Spencer DA, Kim JW, Han Y, Yu D, Ahmed AU, Aboody KS, Lesniak MS. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells 2015; 33:2985-94. [PMID: 26260958 DOI: 10.1002/stem.2109] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Accepted: 06/23/2015] [Indexed: 12/26/2022]
Abstract
The treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer has been revolutionized by trastuzumab. However, longer survival of these patients now predisposes them to forming HER2 positive brain metastases, as the therapeutic antibodies cannot cross the blood brain barrier. The current oncologic repertoire does not offer a rational, nontoxic targeted therapy for brain metastases. In this study, we used an established human neural stem cell line, HB1.F3 NSCs and generated a stable pool of cells secreting a high amount of functional full-length anti-HER2 antibody, equivalent to trastuzumab. Anti-HER2Ab secreted by the NSCs (HER2Ab-NSCs) specifically binds to HER2 overexpressing human breast cancer cells and inhibits PI3K-Akt signaling. This translates to HER2Ab-NSC inhibition of breast cancer cell growth in vitro. Preclinical in vivo experiments using HER2Ab overexpressing NSCs in a breast cancer brain metastases (BCBM) mouse model demonstrate that intracranial injection of HER2Ab-NSCs significantly improves survival. In effect, these NSCs provide tumor localized production of HER2Ab, minimizing any potential off-target side effects. Our results establish HER2Ab-NSCs as a novel, nontoxic, and rational therapeutic approach for the successful treatment of HER2 overexpressing BCBM, which now warrants further preclinical and clinical investigation.
Collapse
Affiliation(s)
- Deepak Kanojia
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | | | - Ramin A Morshed
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | - Richard T Frank
- Department of Neurosciences and Division of Neurosurgery, Beckman Research Institute of the City of Hope, Duarte, California, USA
| | - Dou Yu
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | - Lingjiao Zhang
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | - Drew A Spencer
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | - Julius W Kim
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | - Yu Han
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | - Dihua Yu
- Department of Molecular and Cellular Oncology, The Univ. Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Atique U Ahmed
- Brain Tumor Center, The University of Chicago, Illinois, USA
| | - Karen S Aboody
- Department of Neurosciences and Division of Neurosurgery, Beckman Research Institute of the City of Hope, Duarte, California, USA
| | | |
Collapse
|
121
|
Mehta AI, Linninger A, Lesniak MS, Engelhard HH. Current status of intratumoral therapy for glioblastoma. J Neurooncol 2015; 125:1-7. [DOI: 10.1007/s11060-015-1875-1] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2015] [Accepted: 07/26/2015] [Indexed: 12/26/2022]
|
122
|
Vemulkar T, Mansell R, Petit DCMC, Cowburn RP, Lesniak MS. Highly tunable perpendicularly magnetized synthetic antiferromagnets for biotechnology applications. Appl Phys Lett 2015; 107:012403. [PMID: 26221056 PMCID: PMC4499039 DOI: 10.1063/1.4926336] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 06/24/2015] [Indexed: 05/29/2023]
Abstract
Magnetic micro and nanoparticles are increasingly used in biotechnological applications due to the ability to control their behavior through an externally applied field. We demonstrate the fabrication of particles made from ultrathin perpendicularly magnetized CoFeB/Pt layers with antiferromagnetic interlayer coupling. The particles are characterized by zero moment at remanence, low susceptibility at low fields, and a large saturated moment created by the stacking of the basic coupled bilayer motif. We demonstrate the transfer of magnetic properties from thin films to lithographically defined 2 μm particles which have been lifted off into solution. We simulate the minimum energy state of a synthetic antiferromagnetic bilayer system that is free to rotate in an applied field and show that the low field susceptibility of the system is equal to the magnetic hard axis followed by a sharp switch to full magnetization as the field is increased. This agrees with the experimental results and explains the behaviour of the particles in solution.
Collapse
Affiliation(s)
- T Vemulkar
- Cavendish Laboratory, University of Cambridge , JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - R Mansell
- Cavendish Laboratory, University of Cambridge , JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - D C M C Petit
- Cavendish Laboratory, University of Cambridge , JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - R P Cowburn
- Cavendish Laboratory, University of Cambridge , JJ Thomson Avenue, Cambridge CB3 0HE, United Kingdom
| | - M S Lesniak
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine , Chicago, Illinois 60637, USA
| |
Collapse
|
123
|
Lukas RV, Mehta MP, Lesniak MS. Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. Neurooncol Pract 2015; 2:57-61. [PMID: 27621837 PMCID: PMC5013812 DOI: 10.1093/nop/npv009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Indexed: 11/13/2022] Open
Abstract
INTRODUCTION The 19th Annual Meeting of the Society for Neuro-Oncology (SNO) took place in November of 2014. The focus of many abstracts, as well as the Education Day, was on recent advances in the study of central nervous system (CNS) metastases. TUMOR BIOLOGY Key studies evaluating the factors in tumors and their microenvironment associated with the development and growth of brain metastases are reviewed. PROGNOSTICATION Studies investigating the factors that independently influence survival in participants with brain metastases are presented. RESPONSE ASSESSMENT The Response Assessment for Neuro-Oncology criteria for brain metastases (RANO-BM) and the Neurological Assessment in Neuro-Oncology (NANO) criteria, which were both presented, are recapped. RADIOTHERAPY Studies are reviewed evaluating factors that influence survival outcomes in participants with brain metastases who were treated with radiotherapy. Studies investigating the potential risk of radiation necrosis with the combination of radiotherapy and immunotherapies are presented. SYSTEMIC THERAPIES Brain metastases-focused subset analyses from the ASCEND-1 trial for ALK-translocated non-small cell lung cancer are presented. Preclinical and clinical work on solid tumor leptomeningeal carcinomatosis is also covered. SEQUELAE OF CENTRAL NERVOUS SYSTEM METASTASES AND THEIR TREATMENTS An overview is provided of treatment- related toxicities as well as important concepts that may influence strategies to protect against these toxicities. CONCLUSIONS Key concepts regarding tumor biology, prognostication, response assessment, therapeutic management, and sequelae of treatment for CNS metastases are summarized. Advances in our understanding of the basic and clinical science of CNS metastases have the potential to improve outcomes for patients.
Collapse
Affiliation(s)
- Rimas V. Lukas
- Department of Neurology, University of Chicago, Chicago, Illinois (R.V.L.); Section of Neurosurgery, University of Chicago, Chicago, Illinois (M.S.L.); Department of Radiation Oncology, University of Maryland, Baltimore, Maryland (M.P.M.)
| | - Minesh P. Mehta
- Department of Neurology, University of Chicago, Chicago, Illinois (R.V.L.); Section of Neurosurgery, University of Chicago, Chicago, Illinois (M.S.L.); Department of Radiation Oncology, University of Maryland, Baltimore, Maryland (M.P.M.)
| | - Maciej S. Lesniak
- Department of Neurology, University of Chicago, Chicago, Illinois (R.V.L.); Section of Neurosurgery, University of Chicago, Chicago, Illinois (M.S.L.); Department of Radiation Oncology, University of Maryland, Baltimore, Maryland (M.P.M.)
| |
Collapse
|
124
|
Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 2015; 15:741-52. [PMID: 26027432 DOI: 10.1586/14737175.2015.1051968] [Citation(s) in RCA: 183] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Glioma stem cells (GSCs) constitute a slow-dividing, small population within a heterogeneous glioblastoma. They are able to self-renew, recapitulate a whole tumor, and differentiate into other specific glioblastoma multiforme (GBM) subpopulations. Therefore, they have been held responsible for malignant relapse after primary standard therapy and the poor prognosis of recurrent GBM. The failure of current therapies to eliminate specific GSC subpopulations has been considered a major factor contributing to the inevitable recurrence in GBM patients after treatment. Here, we discuss the molecular mechanisms of chemoresistance of GSCs and the reasons why complete eradication of GSCs is so difficult to achieve. We will also describe the targeted therapies currently available for GSCs and possible mechanisms to overcome such chemoresistance and avoid therapeutic relapse.
Collapse
Affiliation(s)
- Brenda Auffinger
- The Brain Tumor Center, The University of Chicago, 5841 South Maryland Ave, M/C 3026, Chicago, IL 60637, USA
| | | | | | | | | |
Collapse
|
125
|
Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, Pytel P, Han Y, Tobias A, Zhang L, Qiao J, Lesniak MS. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. J Immunol 2015; 195:367-76. [PMID: 26026061 DOI: 10.4049/jimmunol.1401607] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Accepted: 05/02/2015] [Indexed: 12/20/2022]
Abstract
Dendritic cells (DCs) are professional APCs that are traditionally divided into two distinct subsets, myeloid DC (mDCs) and plasmacytoid DC (pDCs). pDCs are known for their ability to secrete large amounts of IFN-α. Apart from IFN-α production, pDCs can also process Ag and induce T cell immunity or tolerance. In several solid tumors, pDCs have been shown to play a critical role in promoting tumor immunosuppression. We investigated the role of pDCs in the process of glioma progression in the syngeneic murine model of glioma. We show that glioma-infiltrating pDCs are the major APC in glioma and are deficient in IFN-α secretion (p < 0.05). pDC depletion leads to increased survival of the mice bearing intracranial tumor by decreasing the number of regulatory T cells (Tregs) and by decreasing the suppressive capabilities of Tregs. We subsequently compared the ability of mDCs and pDCs to generate effective antiglioma immunity in a GL261-OVA mouse model of glioma. Our data suggest that mature pDCs and mDCs isolated from naive mice can be effectively activated and loaded with SIINFEKL Ag in vitro. Upon intradermal injection in the hindleg, a fraction of both types of DCs migrate to the brain and lymph nodes. Compared to mice vaccinated with pDC or control mice, mice vaccinated with mDCs generate a robust Th1 type immune response, characterized by high frequency of CD4(+)T-bet(+) T cells and CD8(+)SIINFEKEL(+) T cells. This robust antitumor T cell response results in tumor eradication and long-term survival in 60% of the animals (p < 0.001).
Collapse
Affiliation(s)
- Mahua Dey
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Alan L Chang
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Jason Miska
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Derek A Wainwright
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Atique U Ahmed
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Irina V Balyasnikova
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Peter Pytel
- Department of Pathology, University of Chicago, Chicago, IL 60637
| | - Yu Han
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Alex Tobias
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Lingjiao Zhang
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Jian Qiao
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| | - Maciej S Lesniak
- Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, IL 60637; and
| |
Collapse
|
126
|
Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, M Nettlebeck D, Han Y, Zhang L, Lesniak MS. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. Oncoimmunology 2015; 4:e1022302. [PMID: 26405578 DOI: 10.1080/2162402x.2015.1022302] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Revised: 02/17/2015] [Accepted: 02/17/2015] [Indexed: 02/06/2023] Open
Abstract
Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor and is associated with poor survival. Virotherapy is a promising candidate for the development of effective, novel treatments for GBM. Recent studies have underscored the potential of virotherapy in enhancing antitumor immunity despite the fact that its mechanisms remain largely unknown. Here, using a syngeneic GBM mouse model, we report that intratumoral virotherapy significantly modulates the tumor microenvironment. We found that intratumoral administration of an oncolytic adenovirus, AdCMVdelta24, decreased tumor-infiltrating CD4+ Foxp3+ regulatory T cells (Tregs) and increased IFNγ-producing CD8+ T cells in treated tumors, even in late stage disease in which a highly immunosuppressive tumor microenvironment is considered to be a significant barrier to immunotherapy. Importantly, intratumoral AdCMVdelta24 treatment augmented systemically transferred tumor-antigen-specific T cell therapy. Furthermore, mechanistic studies showed (1) downregulation of Foxp3 in Tregs that were incubated with media conditioned by virus-infected tumor cells, (2) downregulation of indoleamine 2,3 dioxygenase 1 (IDO) in glioma cells upon infection by AdCMVdelta24, and (3) reprograming of Tregs from an immunosuppressive to a stimulatory state. Taken together, our findings demonstrate the potency of intratumoral oncolytic adenoviral treatment in enhancing antitumor immunity through the regulation of multiple aspects of immune suppression in the context of glioma, supporting further clinical development of oncolytic adenovirus-based immune therapies for malignant brain cancer.
Collapse
Affiliation(s)
- Jian Qiao
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Mahua Dey
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Alan L Chang
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Julius W Kim
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Jason Miska
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Alex Ling
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Dirk M Nettlebeck
- Oncolytic Adenovirus Group; German Cancer Research Center (DKFZ) ; Heidelberg, Germany
| | - Yu Han
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Lingjiao Zhang
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| | - Maciej S Lesniak
- The Brain Tumor Center; Pritzker School of Medicine; The University of Chicago ; Chicago, IL USA
| |
Collapse
|
127
|
Kim JW, Kane JR, Young JS, Chang AL, Kanojia D, Qian S, Spencer DA, Ahmed AU, Lesniak MS. Neural stem cell-mediated delivery of oncolytic adenovirus. ACTA ACUST UNITED AC 2015; 85:13.11.1-13.11.9. [PMID: 25827347 DOI: 10.1002/0471142905.hg1311s85] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The use of stem cells (SCs) as carriers for therapeutic agents has now progressed to early clinical trials. These clinical trials exploring SC-mediated delivery of oncolytic adenoviruses will commence in the near future, hopefully yielding meritorious results that can provoke further scientific inquiry. Preclinical animal studies have demonstrated that SCs can be successfully loaded with conditionally-replicative adenoviruses and delivered to the tumor, whereupon they may evoke pronounced therapeutic efficacy. In this protocol, we describe the maintenance of SCs, provide an analysis of optimal adenoviral titers for SC loading, and evaluate the optimized viral loading on SCs.
Collapse
Affiliation(s)
- Julius W Kim
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - J Robert Kane
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - Jacob S Young
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - Alan L Chang
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - Deepak Kanojia
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - Shuo Qian
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - Drew A Spencer
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - Atique U Ahmed
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| | - Maciej S Lesniak
- The Brain Tumor Center, University of Chicago, Chicago, Illinois
| |
Collapse
|
128
|
Kanojia D, Morshed RA, Zhang L, Miska JM, Qiao J, Kim JW, Pytel P, Balyasnikova IV, Lesniak MS, Ahmed AU. βIII-Tubulin Regulates Breast Cancer Metastases to the Brain. Mol Cancer Ther 2015; 14:1152-61. [PMID: 25724666 DOI: 10.1158/1535-7163.mct-14-0950] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 02/18/2015] [Indexed: 01/11/2023]
Abstract
Brain metastases occur in about 10% to 30% of breast cancer patients, which culminates in a poor prognosis. It is, therefore, critical to understand the molecular mechanisms underlying brain metastatic processes to identify relevant targets. We hypothesized that breast cancer cells must express brain-associated markers that would enable their invasion and survival in the brain microenvironment. We assessed a panel of brain-predominant markers and found an elevation of several neuronal markers (βIII-tubulin, Nestin, and AchE) in brain metastatic breast cancer cells. Among these neuronal predominant markers, in silico analysis revealed overexpression of βIII-tubulin (TUBB3) in breast cancer brain metastases (BCBM) and its expression was significantly associated with distant metastases. TUBB3 knockdown studies were conducted in breast cancer models (MDA-Br, GLIM2, and MDA-MB-468), which revealed significant reduction in their invasive capabilities. MDA-Br cells with suppressed TUBB3 also demonstrated loss of key signaling molecules such as β3 integrin, pFAK, and pSrc in vitro. Furthermore, TUBB3 knockdown in a brain metastatic breast cancer cell line compromised its metastatic ability in vivo, and significantly improved survival in a brain metastasis model. These results implicate a critical role of TUBB3 in conferring brain metastatic potential to breast cancer cells.
Collapse
Affiliation(s)
- Deepak Kanojia
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Ramin A Morshed
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Lingjiao Zhang
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Jason M Miska
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Jian Qiao
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Julius W Kim
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| | - Peter Pytel
- Department of Pathology, University of Chicago Medical Center, Chicago, Illinois
| | | | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois.
| | - Atique U Ahmed
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois
| |
Collapse
|
129
|
Abstract
In 1908, Oluf Bang and Vilhelm Ellerman laid the foundation for theory of oncoviruses by demonstrating that the avian erythroblastosis (a form of chicken leukaemia) could be transmitted by cell-free extracts. Since then, it has been shown very convincingly that viruses can directly cause several human cancers by various mechanisms. Epidemiological data imply that viruses are the second most important risk factor for cancer development in humans, exceeded only by tobacco consumption. Although the ability of certain viruses (hepatitis B and C, human papillomavirus, etc) to cause cancer has been time tested and proven scientifically, there are several other potential viral candidates whose role in oncogenesis is more controversial. One such controversial scenario involves the role of cytomegalovirus (CMV) in malignant gliomas, the most common form of primary brain tumour. CMV first attracted attention about a decade ago when CMV gene products were found in glioma tissue but not in normal brain. Since this initial observation, several different groups have shown an oncomodulatory effect of CMV; however, direct association between CMV infection and incidence of glioma is lacking. In this review, we will evaluate the evidence, both preclinical and clinical, regarding the possible role of CMV in gliomagenesis and maintenance. We will also critically evaluate the rationale for using antiviral drugs in the treatment of patients with glioma.
Collapse
Affiliation(s)
- Mahua Dey
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA
| | - Atique U Ahmed
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA
| | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
130
|
Abstract
Many different experimental molecular therapeutic approaches have been evaluated in an attempt to treat brain cancer. However, despite the success of these experimental molecular therapies, research has shown that the specific and efficient delivery of therapeutic agents to tumor cells is a limitation. In this regard, cell carrier systems have garnered significant attraction due to their capacity to be loaded with therapeutic agents and carry them specifically to tumor sites. Furthermore, cell carriers can be genetically modified to express therapeutic agents that can directly eradicate cancerous cells or can modulate tumor microenvironments. This review describes the current state of cell carriers, their use as vehicles for the delivery of therapeutic agents to brain tumors, and future directions that will help overcome the present obstacles to cell carrier mediated therapy for brain cancer.
Collapse
Affiliation(s)
- Jacob S Young
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | | | | | | |
Collapse
|
131
|
Cheng Y, Dai Q, Morshed R, Fan X, Wegscheid ML, Wainwright DA, Han Y, Zhang L, Auffinger B, Tobias AL, Rincón E, Thaci B, Ahmed AU, Warnke P, He C, Lesniak MS. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small 2014; 10:5137-50. [PMID: 25104165 PMCID: PMC4268041 DOI: 10.1002/smll.201400654] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2014] [Revised: 06/27/2014] [Indexed: 05/19/2023]
Abstract
The blood-brain barrier (BBB) remains a formidable obstacle in medicine, preventing efficient penetration of chemotherapeutic and diagnostic agents to malignant gliomas. Here, a transactivator of transcription (TAT) peptide-modified gold nanoparticle platform (TAT-Au NP) with a 5 nm core size is demonstrated to be capable of crossing the BBB efficiently and delivering cargoes such as the anticancer drug doxorubicin (Dox) and Gd(3+) contrast agents to brain tumor tissues. Treatment of mice bearing intracranial glioma xenografts with pH-sensitive Dox-conjugated TAT-Au NPs via a single intravenous administration leads to significant survival benefit when compared to the free Dox. Furthermore, it is demonstrated that TAT-Au NPs are capable of delivering Gd(3+) chelates for enhanced brain tumor imaging with a prolonged retention time of Gd(3+) when compared to the free Gd(3+) chelates. Collectively, these results show promising applications of the TAT-Au NPs for enhanced malignant brain tumor therapy and non-invasive imaging.
Collapse
Affiliation(s)
| | | | - Ramin Morshed
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Xiaobing Fan
- Department of Radiology, The University of Chicago, Chicago, Illinois, USA
| | - Michelle L. Wegscheid
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Derek A. Wainwright
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Yu Han
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Lingjiao Zhang
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Brenda Auffinger
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Alex L. Tobias
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Esther Rincón
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Bart Thaci
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Atique U. Ahmed
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| | - Peter Warnke
- Department of Surgery, The University of Chicago, Chicago, Illinois, USA
| | - Chuan He
- Department of Chemistry, Institute of Biophysics Dynamics and Howard Hughes Medical Institute, The University of Chicago, Chicago, Illinois, USA
| | - Maciej S. Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA, Fax: +1 773 834 2608
| |
Collapse
|
132
|
Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, Lesniak MS, Wainwright DA. The role of IDO in brain tumor immunotherapy. J Neurooncol 2014; 123:395-403. [PMID: 25519303 DOI: 10.1007/s11060-014-1687-8] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2014] [Accepted: 12/14/2014] [Indexed: 01/23/2023]
Abstract
Malignant glioma comprises the majority of primary brain tumors. Coincidently, most of those malignancies express an inducible tryptophan catabolic enzyme, indoleamine 2,3 dioxygenase 1 (IDO1). While IDO1 is not normally expressed at appreciable levels in the adult central nervous system, it's rapidly induced and/or upregulated upon inflammatory stimulus. The primary function of IDO1 is associated with conversion of the essential amino acid, tryptophan, into downstream catabolites known as kynurenines. The depletion of tryptophan and/or accumulation of kynurenine has been shown to induce T cell deactivation, apoptosis and/or the induction of immunosuppressive programming via the expression of FoxP3. This understanding has informed immunotherapeutic design for the strategic development of targeted molecular therapeutics that inhibit IDO1 activity. Here, we review the current knowledge of IDO1 in brain tumors, pre-clinical studies targeting this enzymatic pathway, alternative tryptophan catabolic mediators that compensate for IDO1 loss and/or inhibition, as well as proposed clinical strategies and questions that are critical to address for increasing future immunotherapeutic effectiveness in patients with incurable brain cancer.
Collapse
Affiliation(s)
- Lijie Zhai
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 300 East Superior Street, Tarry Building 2-703, Chicago, IL, 60611, USA
| | | | | | | | | | | | | | | |
Collapse
|
133
|
Abstract
Chemokines play a vital role in tumor progression and metastasis. Chemokines are involved in the growth of many cancers including breast cancer, ovarian cancer, pancreatic cancer, melanoma, lung cancer, gastric cancer, acute lymphoblastic leukemia, colon cancer, non-small lung cancer, non-hodgkin's lymphoma, etc. The expression of chemokines and their receptors is altered in many malignancies and leads to aberrant chemokine receptor signaling. This review focuses on the role of chemokines in key processes that facilitate tumor progression including proliferation, senescence, angiogenesis, epithelial mesenchymal transition, immune evasion and metastasis.
Collapse
Affiliation(s)
- Purvaba J Sarvaiya
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA
| | | | | | | | | |
Collapse
|
134
|
Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB, Lesniak MS. Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 2014; 6:679-85. [PMID: 17404502 DOI: 10.4161/cbt.6.5.3957] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE Transcriptional targeting is a key strategy to enhance therapeutic efficacy of gene therapy applications. In the context of oncolytic virotherapy, transcriptional promoter elements are used from genes that are over expressed in a variety of malignant cancers. In the present study, we examined the feasibility of transcriptional targeting to glioma cells by comparing the activity of survivin, midkine, and CXCR4 tumor-specific promoters. METHODS To evaluate the expression level of several glioma related genes, we performed quantitative RT-PCR analyses on samples obtained from cell lines and patients. To determine specific level of gene expression mediated by selective promoter elements, we measured luciferase expression in glioma samples transduced with replication deficient adenoviral vectors. Finally, we incorporated the optimal promoters into a conditionally replicative adenoviral vector, CRAd-5/3, and examined the cytopathic effect in vitro. RESULTS The survivin promoter demonstrated the highest level of mRNA expression in primary tumor samples and cell lines. Transcriptional targeting was confirmed by infection of glioma cells with an adenovirus expression vector containing a surviving-driven luciferase reporter gene. Of the tested promoters, minimal level of survivin activity was detected in normal human liver and brain. A novel vector, CRAd-survivin5/3, with E1a under the control of the survivin promoter, exhibited enhanced cytopathic effect in vitro. CONCLUSIONS Our data demonstrate that the survivin promoter element is very active in glioma samples and has low activity in normal human brain and liver. A novel oncolytic virus, CRAd-survivin-5/3, was effective against a panel of glioma cell lines in vitro. Our results suggest that employing the survivin promoter element in the context of CRAd-5/3 may present a new opportunity for the development of glioma specific oncolytic vectors.
Collapse
Affiliation(s)
- Ilya V Ulasov
- Division of Neurosurgery, The University of Chicago, Chicago, Illinois 60637, USA
| | | | | | | | | | | | | |
Collapse
|
135
|
Deheeger M, Lesniak MS, Ahmed AU. Cellular plasticity regulated cancer stem cell niche: a possible new mechanism of chemoresistance. ACTA ACUST UNITED AC 2014; 1. [PMID: 26161429 DOI: 10.14800/ccm.295] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The cancer stem cell (CSC) theory is an emerging concept that proposes a hierarchical nature of carcinogenesis, where a small number of tumor cells are capable of driving tumor growth. Despite many unanswered questions surrounding the cancer stem cell model, the hypothesis has rejuvenated hopes for formulating a novel therapeutic strategy for targeting the roots of cancer. This model predicts that cancer stem cells have the capacity to resist conventional radio- and chemotherapy and initiate disease recurrence. We recently investigated the mechanisms of chemoresistance in glioblastoma (GBM), the most common and aggressive adult human brain tumor. Exposure of patient derived glioma xenograft lines to a therapeutic dose of temolozolomide (TMZ), the most commonly used chemotherapy for patients with GBM, consistently increased the glioma stem cell (GSC) frequency over time. Lineage tracing analysis at the single sell level revealed unprecedented cellular plasticity within the glioma cells, allowing them to reprogram from a differentiated state to an undifferentiated CSC-like state. This reprogramming, mediated by cellular plasticity, is driven by TMZ-induced hypoxia inducible factors (HIFs), and provides a novel mechanism for chemoresistance acquisition. We herein discuss the possible role of temozolomide in regulating a cancer stem cell niche that supports GSC resistance, proliferation, and subsequent therapeutic relapse.
Collapse
Affiliation(s)
- Marc Deheeger
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA
| | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA ; Department of Surgery, The University of Chicago, Chicago, Illinois, USA
| | - Atique U Ahmed
- The Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA ; Department of Surgery, The University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
136
|
Chang AL, Wainwright DA, Dey M, Han Y, Lesniak MS. Abstract 1091: CCR4+ regulatory T cells progressively accumulate in the presence of leukocyte-derived CCL22/CCL17 in an experimental model of glioblastoma multiforme. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-1091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. One hallmark of GBM is the accumulation of infiltrating regulatory T cells (Tregs), a highly immunosuppressive T cell subset that suppresses T cell-mediated GBM rejection. Previous work has demonstrated that the Treg-recruiting chemokine, CCL22, is expressed by patient-resected GBM. Importantly, the number of Tregs expressing CCR4, the cognate chemokine receptor for CCL22 and CCL17, is increased in the peripheral blood of GBM patients. To investigate the therapeutic potential of targeting the CCR4 chemokine-receptor axis in brain tumors, we performed FACS analysis to determine the level of CCR4-expressing Tregs and other T cell populations. In addition, we analyzed the mRNA expression levels of the Treg-recruiting chemokines CCL22 and CCL17 in different cellular populations by Percoll gradient isolation followed by qRT-PCR. Using the orthotopic GL261 model of GBM, we found a progressive accumulation of CCR4+ Tregs in the brain tumor. Coincidently, the expression of CCL17 and CCL22 was predominantly localized to the tumor-infiltrating leukocytes, rather than the tumor tissue itself. Finally, we tested the potential impact of a CCR4 antagonist on Treg recruitment and CD8+/Foxp3+ T cell ratio. We found that CCR4 antagonist treatment was able to increase the CD8+/Foxp3+ T cell ratio during the early time points post-GL261 injection. These results implicate the chemokine receptor CCR4 as a therapeutic target for further investigation as a potential strategy to target Treg trafficking to GBM.
Citation Format: Alan L. Chang, Derek A. Wainwright, Mahua Dey, Yu Han, Maciej S. Lesniak. CCR4+ regulatory T cells progressively accumulate in the presence of leukocyte-derived CCL22/CCL17 in an experimental model of glioblastoma multiforme. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1091. doi:10.1158/1538-7445.AM2014-1091
Collapse
Affiliation(s)
| | | | | | - Yu Han
- University of Chicago, Chicago, IL
| | | |
Collapse
|
137
|
Auffinger B, Tobias AL, Han Y, Lesniak MS, Ahmed AU. Abstract 3899: ROCK inhibitor as a differentiation-inducing agent to target glioma stem cells. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-3899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Only 3% of patients diagnosed each year with Glioblastoma Multiforme (GBM) survive longer than 5 years, making GBM one of the most lethal forms of human cancer. It has been proposed that GBMs are driven by a rare subset of tumor cells referred to as cancer stem cells (CSCs), which have the ability to resist conventional radio- and chemotherapy and initiate disease recurrence. Thus, the development of novel and effective therapeutic strategies targeting CSCs is required and should significantly improve the dismal prognosis for patients with GBM. A possible viable strategy to effectively target glioma stem cells (GSCs) is the use of bone morphogenetic proteins (BMPs) as differentiation inducers. Our results suggest that Rho-associated protein kinase (ROCK) could work as a pharmacological negative regulator of BMPs. Our preliminary data indicate that: i) Fasudil, a ROCK1 inhibitor, induces BMP2 and BMP4 expression both in vitro and in vivo in different human-derived glioma xenograft models; ii) Fasudil-induced BMPs can increase the expression of differentiation markers and decrease stemness in these glioma models; iii) temozolomide, a chemotherapeutic agent, converts glioma cells to a GSC phenotype, while Fasudil blocks this interconversion; iv) co-administration of Fasudil with temozolomide inhibits the invasive characteristics of GBM in an orthotropic glioma xenograft model; and v) the analysis of BMP expression in human-derived GBM samples from the Repository of Molecular Brain Neoplasia Database (REMBRABDT) reveals that patients with higher BMP2 expression survived four times longer than those with low or intermediate BMP2 expression (p<0.001). Based on this, we propose that, by blocking ROCK signaling with the FDA approved pharmacological inhibitor Fasudil, one can modulate BMP expression in human-derived gliomas. Fasudil, therefore, may redirect cellular signals regulating GSCs' stemness, fate, and initiate their differentiation. Such an agent will allow us to develop a more effective anti-glioma therapy through its combination with other conventional anti-cancer drugs.
Citation Format: Brenda Auffinger, Alex L. Tobias, Yu Han, Maciej S. Lesniak, Atique U. Ahmed. ROCK inhibitor as a differentiation-inducing agent to target glioma stem cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3899. doi:10.1158/1538-7445.AM2014-3899
Collapse
Affiliation(s)
| | | | - Yu Han
- University of Chicago, Chicago, IL
| | | | | |
Collapse
|
138
|
Kanojia DP, Sarvaiya P, Qiao J, Zhang L, Balyasnikova I, Lesniak MS. Abstract 2006: The role of neuronal predominant gene expression in breast cancer brain metastasis. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-2006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer brain metastasis (BCBM) occur in about 10-30% of patients with breast cancer. It has been established that breast cancer is a heterogeneous disease with 3 predominant subtypes (1) ER/PR positive (3) HER2 positive (4) Triple negative breast cancer (TNBC)/Basal subtype. TNBC is associated with the highest incidence of metastasis to brain, mechanism of which is poorly understood. Therefore, in order to understand the proclivity of TNBC to the brain and identify potential targets for treatment BCMB, we employed two widely used paired cell model system, the MDA-MB-231/MDA-MB-231BrM2 and the CN-34/CN34BrM2. The levels of brain predominant markers [ST6GALNAC5 (ST6), Nestin, Tubulin β3 (TUBB3)] in brain-derived clones were assesed by qRT-PCR and found to be overexpressed in brain-derived MDA-MB-231BrM2 and CN34BrM2 in comparison with parental breast cancer cell lines. We also identified hyperactivated TGF-β signaling in brain derived clones in comparison with parental cells. Moreover, the treatment of parental cells with TGF-β increased the expression of ST6, Nestin and TUBB3 indicating that TGF-β plays role in the development of BCBM. To further delineate the role of these markers in BCBM, knockdown experiments using two different shRNA specific to TUBB3 (neuronal specific) were performed. TUBB3 knockdown resulted in a dramatic reduction in tumorspheres formation, migration, invasion and the ability to adhere to laminin in both MDA-MB-231BrM2. Furthermore, the downregulation of expression of β1 and β3 integrins in TUBB3 knockdown cells was discovered as assessed by qPCR and flow cytometry. These results implicate that overexpression of brain specific TUBB3 provides breast cancer cells with migration and invasion abilities and a possible survival advantage in the brain microenvironment.
Citation Format: Deepak P. Kanojia, Purva Sarvaiya, Jian Qiao, Lingjiao Zhang, Irina Balyasnikova, Maciej S. Lesniak. The role of neuronal predominant gene expression in breast cancer brain metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2006. doi:10.1158/1538-7445.AM2014-2006
Collapse
|
139
|
Sengupta S, Balyasnikova I, Naheed S, Lesniak MS, Junghans RP, Sampath P. Abstract 2798: Targeting IL13R alpha2 heterogeneity in malignant glioma with engineered T cells. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-2798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A majority of malignant glioma exclusively expresses Interleukin 13 receptor alpha chain variant 2 (IL13Rα2), making it an ideal candidate for targeted immunotherapy. A number of immunotherapeutic molecules have been developed against IL13Rα2 with varied levels of therapeutic efficacy. However, the importance of IL13Rα2 as a successful immunotherapy candidate is under scrutiny due to its heterogeneous expression on the tumor. We have used an IL13-chimeric antigen receptor (IL13CAR) expressing T cells to target the IL13Rα2 heterogeneity on malignant glioma. IL13Rα2 was over-expressed on U251MG human glioma cell line by stable transfection (IL13Rα2Hi) to evaluate the effects of its increased expression in tumor progression and immunotherapeutic efficacy, compared to the regular U251 cells (IL13Rα2Lo) and IL13Rα2-knocked down U251 cells (IL13Rα2KD). Tumor cells readily formed neurospheres under established culture conditions. Increased expression of IL13Rα2 was observed in IL13Rα2Hi-neurosphere derived tumor cells when compared to those derived from IL13Rα2Lo neurospheres, as well as the parental IL13Rα2Hi cells. IL13Rα2Hi-neurosphere derived tumor cells were also resistant to radiation therapy and temozolomide chemotherapy when compared to those IL13Rα2Lo neurospheres-derived tumor cells, as well as parental cell lines. Higher levels of IFN gamma and TNF alpha in the culture supernatants, increased T cell proliferation, and CAR+ TCR enrichment were observed when IL13CAR T cells were co-cultured with IL13Rα2Hi-neurosphere derived tumor cells, in comparison to co-culture with IL13Rα2Lo -neurosphere derived tumor cells, as well as the parental cells. IL13CAR T cells, upon co-culture with IL13Rα2Hi-neurosphere derived tumor cells exerted highest levels of cytotoxicity. Together, these results predict that IL13Rα2 heterogeneity can be addressed by a combination of established therapeutic regimen and targeted immunotherapy. While those cells expressing lower levels of IL13Rα2 are susceptible to radiation and chemotherapy, the high IL13Rα2-expressing tumor cells that escape these treatments can be candidates for IL13Rα2-targeted immunotherapy.
Note: This abstract was not presented at the meeting.
Citation Format: Sadhak Sengupta, Irina Balyasnikova, Seema Naheed, Maciej S. Lesniak, Richard P. Junghans, Prakash Sampath. Targeting IL13R alpha2 heterogeneity in malignant glioma with engineered T cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2798. doi:10.1158/1538-7445.AM2014-2798
Collapse
Affiliation(s)
- Sadhak Sengupta
- 1Roger Williams Medical Center, Boston University School of Medicine, Providence, RI
| | | | - Seema Naheed
- 1Roger Williams Medical Center, Boston University School of Medicine, Providence, RI
| | | | - Richard P. Junghans
- 1Roger Williams Medical Center, Boston University School of Medicine, Providence, RI
| | - Prakash Sampath
- 1Roger Williams Medical Center, Boston University School of Medicine, Providence, RI
| |
Collapse
|
140
|
Moon KS, Wainwright DA, Balyasnikova IV, Kim CK, Ko YS, Kim KK, Lesniak MS. Abstract LB-64: Immune modulatory effects of mesenchymal stem cells on regulatory T cells in mouse glioma model. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-lb-64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective: Although mesenchymal stem cells (MSCs) have been investigated as a vector in stem cell-based therapy for malignant glioma, there has been a debate about the exact role of MSCs in tumor microenvironment. From an immunnological aspect, MSCs have been reported to inhibit T cell proliferation and to increase CD4+FoxP3+ regulatory T cells (Tregs). They also have been investigated as a potent immune suppressor in several clinical situations including autoimmune diseases. However, whether MSCs have an immune modulatory effect on Tregs in malignant gliomas or not has not been established.
Materials & methods: The author explored the impact of MSCs on freshly sorted CD4+ T cells or already activated Tregs in vitro to determine whether MSCs have different influences on naive T cells and Tregs. Furthermore, using orthotropic mouse glioma model, the author investigated MSC's effect on Tregs during tumor progression.
Results: The authors observed that MSCs decreased Treg conversion from naive T cells and Treg proliferation, without affecting the proportion of natural / induced Treg [nTreg; CD4+FoxP3+Helios+ / iTreg; CD4+FoxP3+Helios-]. When co-cultured with already activated Tregs, however, MSCs did not affect Treg induction and proliferation, but decreased the proportion of iTreg. With an intracranially implanted GL261 cell-based orthotropic mouse model, co-injection of MSCs with tumor cell implantation slightly increased Treg recruit into the tumor and decreased the proportion of iTreg. When MSCs were injected after glioma formation, there was no significant effect of MSCs on Treg recruit and phenotypic changes. Furthermore, there was a lower level of cytokine expressions including TGF-β, INF-γ, IL-2, and IL-1β in Tregs cocultured with MSCs than that in solely cultured Tregs. Increased gene expression of IL-6, CCL17, and TGF-β, or decreased gene expression of CCL2 in MSCs may be relevant to the phenotypic changes of cocultured Tregs.
Conclusions: This study demonstrates that MSCs mainly inhibit iTreg, leading to a relative increase of the proportion of nTregs in mouse glioma model, possibly throughIL-6 signaling pathway. With a better understanding for critical factors and immunological consequences for the altered Treg phenotype in glioma, future experiments will be needed to elucidate the immunological impact of MSCs on Tregs in malignant glioma.
Citation Format: Kyung-Sub Moon, Derek A. Wainwright, Irina V. Balyasnikova, Chung Kwon Kim, Yoo Seung Ko, Kyung Keun Kim, Maciej S. Lesniak. Immune modulatory effects of mesenchymal stem cells on regulatory T cells in mouse glioma model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-64. doi:10.1158/1538-7445.AM2014-LB-64
Collapse
Affiliation(s)
- Kyung-Sub Moon
- 1Chonnam National University Hwasun Hospital & Medical School, Hwasun-gun, Republic of Korea
| | - Derek A. Wainwright
- 2The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL
| | - Irina V. Balyasnikova
- 2The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL
| | - Chung Kwon Kim
- 2The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL
| | - Yoo Seung Ko
- 3Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwang-ju, Republic of Korea
| | - Kyung Keun Kim
- 3Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwang-ju, Republic of Korea
| | - Maciej S. Lesniak
- 2The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL
| |
Collapse
|
141
|
Young JS, Morshed RA, Kim JW, Balyasnikova IV, Ahmed AU, Lesniak MS. Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy. Expert Opin Drug Deliv 2014; 11:1733-46. [PMID: 25005767 DOI: 10.1517/17425247.2014.937420] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
INTRODUCTION A limitation of small molecule inhibitors, nanoparticles (NPs) and therapeutic adenoviruses is their incomplete distribution within the entirety of solid tumors such as malignant gliomas. Currently, cell-based carriers are making their way into the clinical setting as they offer the potential to selectively deliver many types of therapies to cancer cells. AREAS COVERED Here, we review the properties of stem cells, induced pluripotent stem cells and engineered cells that possess the tumor-tropic behavior necessary to serve as cell carriers. We also report on the different types of therapeutic agents that have been delivered to tumors by these cell carriers, including: i) therapeutic genes; ii) oncolytic viruses; iii) NPs; and iv) antibodies. The current challenges and future promises of cell-based drug delivery are also discussed. EXPERT OPINION While the emergence of stem cell-mediated therapy has resulted in promising preclinical results and a human clinical trial utilizing this approach is currently underway, there is still a need to optimize these delivery platforms. By improving the loading of therapeutic agents into stem cells and enhancing their migratory ability and persistence, significant improvements in targeted cancer therapy may be achieved.
Collapse
Affiliation(s)
- Jacob S Young
- The University of Chicago Pritzker School of Medicine , 5841 South Maryland Ave., M/C 3026, Chicago, IL 60637 , USA
| | | | | | | | | | | |
Collapse
|
142
|
Wainwright DA, Lesniak MS. Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma. Oncoimmunology 2014; 3:e28927. [PMID: 25057450 PMCID: PMC4091585 DOI: 10.4161/onci.28927] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2014] [Accepted: 04/16/2014] [Indexed: 11/22/2022] Open
Abstract
Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.
Collapse
Affiliation(s)
- Derek A Wainwright
- The Brain Tumor Center; The University of Chicago Pritzker School of Medicine; Chicago, IL USA
| | - Maciej S Lesniak
- The Brain Tumor Center; The University of Chicago Pritzker School of Medicine; Chicago, IL USA
| |
Collapse
|
143
|
Wegscheid ML, Morshed RA, Cheng Y, Lesniak MS. The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma. Expert Opin Drug Deliv 2014; 11:957-75. [PMID: 24766329 DOI: 10.1517/17425247.2014.912629] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Malignant gliomas remain one of medicine's most daunting unsolved clinical problems. The development of new technologies is urgently needed to improve the poor prognosis of patients suffering from these brain tumors. Magnetic nanomaterials are appealing due to unique properties that allow for noninvasive brain tumor diagnostics and therapeutics in one multifunctional platform. AREAS COVERED We report on the recent advances of magnetic nanomaterials for brain tumor imaging and therapy, with an emphasis on novel approaches and clinical progress. We detail their biomedical applications including brain tumor targeting, MRI contrast enhancement, optical imaging, magnetic hyperthermia, magnetomechanical destruction, drug delivery, gene therapy, as well as tracking of cell-based and viral-based therapies. The clinical cases and obstacles encountered in the use of magnetic nanomaterials for malignant glioma are also examined. EXPERT OPINION To accelerate the effective translation of these materials to the clinic as theranostics for brain tumors, limitations such as poor intratumoral distribution, targeting efficiency and nonspecific systemic side effects must be addressed. Future innovations should focus on optimizing and combining the unique therapeutic applications of these magnetic nanomaterials as well as improving the selectivity of the system based on the molecular profiling of tumors.
Collapse
|
144
|
Dreixler JC, Poston JN, Balyasnikova I, Shaikh AR, Tupper KY, Conway S, Boddapati V, Marcet MM, Lesniak MS, Roth S. Delayed administration of bone marrow mesenchymal stem cell conditioned medium significantly improves outcome after retinal ischemia in rats. Invest Ophthalmol Vis Sci 2014; 55:3785-96. [PMID: 24699381 DOI: 10.1167/iovs.13-11683] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
PURPOSE Delayed treatment after ischemia is often unsatisfactory. We hypothesized that injection of bone marrow stem cell (BMSC) conditioned medium after ischemia could rescue ischemic retina, and in this study we characterized the functional and histological outcomes and mechanisms of this neuroprotection. METHODS Retinal ischemia was produced in adult Wistar rats by increasing intraocular pressure for 55 minutes. Conditioned medium (CM) from rat BMSCs or unconditioned medium (uCM) was injected into the vitreous 24 hours after the end of ischemia. Recovery was assessed 7 days after ischemia using electroretinography, at which time we euthanized the animals and then prepared 4-μm-thick paraffin-embedded retinal sections. TUNEL and Western blot were used to identify apoptotic cells and apoptosis-related gene expression 24 hours after injections; that is, 48 hours after ischemia. Protein content in CM versus uCM was studied using tandem mass spectrometry, and bioinformatics methods were used to model protein interactions. RESULTS Intravitreal injection of CM 24 hours after ischemia significantly improved retinal function and attenuated cell loss in the retinal ganglion cell layer. CM attenuated postischemic apoptosis and apoptosis-related gene expression. By spectral counting, 19 proteins that met stringent identification criteria were increased in the CM compared to uCM; the majority were extracellular matrix proteins that mapped into an interactional network together with other proteins involved in cell growth and adhesion. CONCLUSIONS By restoring retinal function, attenuating apoptosis, and preventing retinal cell loss after ischemia, CM is a robust means of delayed postischemic intervention. We identified some potential candidate proteins for this effect.
Collapse
Affiliation(s)
- John C Dreixler
- Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, United States
| | - Jacqueline N Poston
- Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States
| | - Irina Balyasnikova
- Department of Surgery (Neurosurgery), The University of Chicago, Chicago, Illinois, United States
| | - Afzhal R Shaikh
- Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, United States
| | - Kelsey Y Tupper
- Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, United States
| | - Sineadh Conway
- Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, United States
| | - Venkat Boddapati
- Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, United States
| | - Marcus M Marcet
- Department of Surgery (Ophthalmology and Visual Science), The University of Chicago, Chicago, Illinois, United States
| | - Maciej S Lesniak
- Department of Surgery (Neurosurgery), The University of Chicago, Chicago, Illinois, United States
| | - Steven Roth
- Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, United States
| |
Collapse
|
145
|
Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, Han Y, Lesniak MS. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20:5290-301. [PMID: 24691018 DOI: 10.1158/1078-0432.ccr-14-0514] [Citation(s) in RCA: 423] [Impact Index Per Article: 42.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
PURPOSE Glioblastoma (GBM) is the most common form of malignant glioma in adults. Although protected by both the blood-brain and blood-tumor barriers, GBMs are actively infiltrated by T cells. Previous work has shown that IDO, CTLA-4, and PD-L1 are dominant molecular participants in the suppression of GBM immunity. This includes IDO-mediated regulatory T-cell (Treg; CD4(+)CD25(+)FoxP3(+)) accumulation, the interaction of T-cell-expressed, CTLA-4, with dendritic cell-expressed, CD80, as well as the interaction of tumor- and/or macrophage-expressed, PD-L1, with T-cell-expressed, PD-1. The individual inhibition of each pathway has been shown to increase survival in the context of experimental GBM. However, the impact of simultaneously targeting all three pathways in brain tumors has been left unanswered. EXPERIMENTAL DESIGN AND RESULTS In this report, we demonstrate that, when dually challenged, IDO-deficient tumors provide a selectively competitive survival advantage against IDO-competent tumors. Next, we provide novel observations regarding tryptophan catabolic enzyme expression, before showing that the therapeutic inhibition of IDO, CTLA-4, and PD-L1 in a mouse model of well-established glioma maximally decreases tumor-infiltrating Tregs, coincident with a significant increase in T-cell-mediated long-term survival. In fact, 100% of mice bearing intracranial tumors were long-term survivors following triple combination therapy. The expression and/or frequency of T cell expressed CD44, CTLA-4, PD-1, and IFN-γ depended on timing after immunotherapeutic administration. CONCLUSIONS Collectively, these data provide strong preclinical evidence that combinatorially targeting immunosuppression in malignant glioma is a strategy that has high potential value for future clinical trials in patients with GBM.
Collapse
Affiliation(s)
- Derek A Wainwright
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Alan L Chang
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Mahua Dey
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Irina V Balyasnikova
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Chung Kwon Kim
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Alex Tobias
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Yu Cheng
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Julius W Kim
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Jian Qiao
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Lingjiao Zhang
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Yu Han
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois
| |
Collapse
|
146
|
Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, Lesniak MS, Ahmed AU. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ 2014; 21:1119-31. [PMID: 24608791 DOI: 10.1038/cdd.2014.31] [Citation(s) in RCA: 244] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2013] [Revised: 02/03/2014] [Accepted: 02/03/2014] [Indexed: 12/28/2022] Open
Abstract
Glioblastoma multiforme patients have a poor prognosis due to therapeutic resistance and tumor relapse. It has been suggested that gliomas are driven by a rare subset of tumor cells known as glioma stem cells (GSCs). This hypothesis states that only a few GSCs are able to divide, differentiate, and initiate a new tumor. It has also been shown that this subpopulation is more resistant to conventional therapies than its differentiated counterpart. In order to understand glioma recurrence post therapy, we investigated the behavior of GSCs after primary chemotherapy. We first show that exposure of patient-derived as well as established glioma cell lines to therapeutic doses of temozolomide (TMZ), the most commonly used antiglioma chemotherapy, consistently increases the GSC pool over time both in vitro and in vivo. Secondly, lineage-tracing analysis of the expanded GSC pool suggests that such amplification is a result of a phenotypic shift in the non-GSC population to a GSC-like state in the presence of TMZ. The newly converted GSC population expresses markers associated with pluripotency and stemness, such as CD133, SOX2, Oct4, and Nestin. Furthermore, we show that intracranial implantation of the newly converted GSCs in nude mice results in a more efficient grafting and invasive phenotype. Taken together, these findings provide the first evidence that glioma cells exposed to chemotherapeutic agents are able to interconvert between non-GSCs and GSCs, thereby replenishing the original tumor population, leading to a more infiltrative phenotype and enhanced chemoresistance. This may represent a potential mechanism for therapeutic relapse.
Collapse
Affiliation(s)
- B Auffinger
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - A L Tobias
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - Y Han
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - G Lee
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - D Guo
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - M Dey
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - M S Lesniak
- 1] The Brain Tumor Center, The University of Chicago, Chicago, IL, USA [2] Department of Surgery, The University of Chicago, Chicago, IL, USA
| | - A U Ahmed
- 1] The Brain Tumor Center, The University of Chicago, Chicago, IL, USA [2] Department of Surgery, The University of Chicago, Chicago, IL, USA
| |
Collapse
|
147
|
Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev 2014; 66:42-57. [PMID: 24060923 PMCID: PMC3948347 DOI: 10.1016/j.addr.2013.09.006] [Citation(s) in RCA: 230] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Revised: 08/28/2013] [Accepted: 09/13/2013] [Indexed: 12/16/2022]
Abstract
Brain tumors are a diverse group of neoplasms that often carry a poor prognosis for patients. Despite tremendous efforts to develop diagnostic tools and therapeutic avenues, the treatment of brain tumors remains a formidable challenge in the field of neuro-oncology. Physiological barriers including the blood-brain barrier result in insufficient accumulation of therapeutic agents at the site of a tumor, preventing adequate destruction of malignant cells. Furthermore, there is a need for improvements in brain tumor imaging to allow for better characterization and delineation of tumors, visualization of malignant tissue during surgery, and tracking of response to chemotherapy and radiotherapy. Multifunctional nanoparticles offer the potential to improve upon many of these issues and may lead to breakthroughs in brain tumor management. In this review, we discuss the diagnostic and therapeutic applications of nanoparticles for brain tumors with an emphasis on innovative approaches in tumor targeting, tumor imaging, and therapeutic agent delivery. Clinically feasible nanoparticle administration strategies for brain tumor patients are also examined. Furthermore, we address the barriers towards clinical implementation of multifunctional nanoparticles in the context of brain tumor management.
Collapse
Affiliation(s)
- Yu Cheng
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - Ramin A Morshed
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - Brenda Auffinger
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - Alex L Tobias
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA
| | - Maciej S Lesniak
- The Brain Tumor Center, The University of Chicago, Chicago, IL, USA.
| |
Collapse
|
148
|
Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther 2014; 21:38-44. [PMID: 24434573 DOI: 10.1038/cgt.2013.81] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2013] [Revised: 12/08/2013] [Accepted: 12/09/2013] [Indexed: 11/09/2022]
Abstract
Myeloid-derived suppressor cells (MDSCs) accumulate in the glioma microenvironment during tumor progression and promote immunosuppression. Interleukin-12 (IL-12) immunogene therapy can alter MDSCs toward an antigen-presenting cell phenotype and these mature cells can have a central role in antigen presentation. It remains unclear, however, how MDSC depletion can affect glioma immunotherapy. In this study, we generated a replication-deficient adenoviral vector, Ad.5/3.cRGD-mIL12p70, that transduces the GL261-based murine glioma cell line, resulting in the induction of biologically active, murine IL12p70 expression. Ex vivo, IL-12 expressed by GL261 cells induced interferon-γ synthesis in CD8(+) T cells (P<0.001), CD4(+) T cells (P=0.009) and natural killer cells (P=0.036). When injected 1 week after tumor implantation, Ad.5/3.cRGD-mIL12p70 successfully prolonged the survival of glioma-bearing mice. Sixty percent of animals treated with IL-12 immunotherapy were long-term survivors over 175 days, whereas all the control group animals expired by 40 days after tumor implantation (P=0.026). Mice receiving Ad.5/3.cRGD-mIL12p70 also accumulated 50% less MDSCs in the brain than the control group (P=0.007). Moreover, in the IL-12 group, MDSCs significantly overexpressed CD80 and major histocompatibility complex class II molecules (P=0.041). Depletion of MDSCs with Gr1(+) antibody had no survival benefit induced by IL-12-mediated immunotherapy. Of note, IL-12 therapy increased the presence of myeloid dendritic cells (mDCs) in the glioma microenvironment (P=0.0069). Ultimately, the data show that in the context of IL-12 immunogene therapy, MDSCs are dispensable and mDCs may provide the majority of antigen presentation in the brain.
Collapse
Affiliation(s)
- B Thaci
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - A U Ahmed
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - I V Ulasov
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - D A Wainwright
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - P Nigam
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - B Auffinger
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - A L Tobias
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - Y Han
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - L Zhang
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - K-S Moon
- 1] The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA [2] Department of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, Jeollanam-do, Korea
| | - M S Lesniak
- The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| |
Collapse
|
149
|
Abstract
The transphenoidal procedure has become the preferred approach in the surgical management of sellar/parasellar tumors. Nevertheless, specific indications remain for the transcranial approach and the objective of this review is to evaluate the available data on outcomes following transcranial or transphenoidal approaches to sellar/parasellar tumors. We assess the indications used for each approach and parameters that favor one over the other. Factors such as tumor size, consistency and configuration are important variables in choosing the transcranial approach. Other important considerations include persistent visual loss after incomplete decompression via the transphenoidal route, ectatic midline carotid arteries, co-existent intracranial aneurysms and sphenoid sinusitis. We review the data on visual and endocrinological outcomes following the transcranial or transphenoidal approach and provide an argument that, while there appears to be a trend towards greater visual improvement after transcranial surgery for large-to-giant pituitary adenomas, this benefit is offset by a greater risk of postoperative pituitary dysfunction. There is no difference in the rate of recurrence between the two procedures in the published literature. Overall, craniotomies will continue to play a role in the management of patients with sellar/parasellar tumors, although patient selection and careful preoperative evaluation are key elements in choosing the most appropriate approach.
Collapse
Affiliation(s)
- Wael Musleh
- The University of Chicago, Division of Neurosurgery, Chicago, IL 60637, USA
| | | | | |
Collapse
|
150
|
Abstract
Oligodendrogliomas are a distinct subgroup of brain tumors with a fairly favorable clinical prognosis. However, these tumor exhibit varying degrees of heterogeneity and their clinical behavior is therefore not always the same. For this reason, genetic markers have been developed to further guide the clinical treatment. One such marker, the 1p and 19q chromosomal deletions, has been well documented in a subset of patients with oligodendrogliomas. Most importantly, patients who exhibit these chromosomal deletions respond favorably to chemotherapy. This article reviews the evidence describing the association of such deletions with a favorable response to chemotherapy and improved prognosis of patients with oligodendrogliomas. In addition, attempts to elucidate the molecular mechanisms behind the biologic behavior of these tumors are further explored.
Collapse
Affiliation(s)
- Adam M Sonabend
- Division of Neurosurgery, The University of Chicago, 5841 S. Maryland Ave., MC 3026, Chicago, IL 60637, USA.
| | | |
Collapse
|